Lynparza PFS tops expectations in SOLO-2

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Lynparza olaparib showed a significant progression-free survival benefit vs. placebo in the Phase III SOLO-2 trial to treat BRCA-mutated metastatic ovarian cancer. The pharma said the median PFS in SOLO-2's Lynparza arm "substantially exceeded" the benefit previously seen in Phase II Study 19.

Data from Study 19 published in 2014 in The Lancet showed that Lynparza led to a median PFS of 11.2 months vs. 4.3 months for placebo (HR=0.18, p<0.0001) among patients with a germline or tumor BRCA mutation. That trial evaluated the PARP inhibitor as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer, and was not restricted to patients with BRCA mutations. ...